David Arkowitz - 04 Feb 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Reporting relationship: Executive Vice President, Chief Financial Officer and Head of Business Development
Issuer ticker: MCRB
Reported as of: 04 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Feb 2022, 20:30:39 UTC
Prior SEC filing: 07 Jun 2021
Next SEC filing: 31 Oct 2022
Source filing: View source filing
Reporting owner signature: /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz

Key filing fact

David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 08 Feb 2022.

Key facts

This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Feb 2022, 20:30.

Change

Previous filing in this sequence was filed on 07 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MCRB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +190,000
Change %
Price: $0.000000
Shares after: 190,000
Date: 04 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 190,000
Exercise price: $7.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

SEC remarks

Executive Vice President, Chief Financial Officer and Head of Business Development